UnityPoint Health Ventures, the venture arm of UnityPoint Health, has invested $1 million in St. Louis-based Epharmix.
Epharmix, a messaging and engagement platform for care managers, is the fourth company to be awarded by the venture fund. UnityPoint Health Ventures has also invested in Pathware, RxRevu and Coralville-based VIDA Diagnostics.
Epharmix’s evidence-based check-ins use text messages to collect patient-reported symptoms and biometrics for 24 different chronic and behavioral health conditions. Care managers receive alerts for patients who are rising risk, allowing for faster outreach to patients.
The strategic partnership will provide Epharmix access to UnityPoint’s extensive and growing network of hospitals and clinics and clinical experts who will contribute important insights on Epharmix’s product development and company growth.
“At the end of the day, our goal is to make it easier for people to live well,” said Matthew Warrens, Managing Director of Innovation at UnityPoint Health. “A big part of our decision to invest in Epharmix was based on our organizations’ strong alignment, especially on care management and population health. We’re excited to partner with Epharmix to bring their simplistic and affordable solutions to our patients and providers.”
Launched in May, UnityPoint Health Ventures is a $100 million venture fund that invests in early-stage companies in four key areas: digital health, medical devices, health care technology systems and healthcare services.
The size of the investment was not disclosed.
UnityPoint Health launches $100 million venture fund -May 23, 2019
Vida Diagnostics receives $1 million investment from UnityPoint Health Ventures -July 25, 2019